HUTCHMED Just Reclaimed the Moving Average That Capped Its Slide— $13.20 Now Decides Whether the GSK Trade Accelerates

HUTCHMED (HCM) is up 6.6% to $13.66 this session, and the move landed in a place worth paying attention to. That print has pushed the stock back above its 200-day moving average—a line at roughly $13.20 that has sat overhead through most of the past year, a quiet ceiling during a prolonged slide. This is not a round number pulled off today's tape; it is a level with a year of trading memory, and the stock is crossing it for the first time on a fresh, company-specific catalyst.

The reason for the pop is a deal, not a vague sector tailwind. On September 3, HUTCHMED signed an exclusive licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody drug, in a transaction worth up to $1.295 billion with a $110 million upfront payment. Shares spiked roughly 15% on the UK listing after the disclosure. That is the kind of validation that reprices a beaten-down biotech—external cash, a big pharma counterparty, and a shot at a real pipeline asset.

Why this breakout reads different from the last five attempts

For the context that matters, look at where the stock came from. Trading as low as $9.77 over the past 52 weeks, HUTCHMED was essentially a year-long downtrend punctuated by lower reactions, until the last three weeks. The 20-day change is now nearly +12%, the 50-day average at $12.00 has curled up under price, and today's candle reclaimed the 200-day that had defined the slide. Read that as a market slowly shifting from "dead money" to "something changed." When price takes back a major moving average that had been rock-solid resistance, the people on the wrong side of that flip are the ones who sold the decline or faded each bounce.

Who is under pressure, specifically? The sellers who shorted into the multi-year weakness and the traders who faded the post-deal spike on September 7, expecting the usual fade. If HCM holds the reclaim, those positions sit against a stock with a fresh external buyer and a 200-day that just turned from supply into the floor. That is a gear change, not just another bounce.

The line that decides: $13.20

Everything now runs through $13.20, the 200-day that HUTCHMED is defending right now. It has memory—it capped rallies for roughly a year—so the reaction around retests becomes meaningful: more orders gather at a level everyone can see.

• Hold above $13.20 through a retest, and the reclaim is real. The stock keeps the upward bias with room to work before the upper half of its 52-week range.
• Lose $13.20 and concede the zone back down toward $13.00–$12.80, and this stops being a breakout and becomes the latest failed reclaim in a year-long saga—sellers who sat on the sideline get their fade back.

Today's high of $13.71 marks the immediate intraday ceiling; a clean close above that extends the move. But the honest caveat for anyone chasing: the clean reclaim trade was struck when price first took the level. At $13.66, you are paying roughly 3.5% above the moving average already. The edge here is not in buying the next tick; it is in letting the retest of $13.20 be the decision.

The trade map

Scenario	Trigger	Path	Invalidation	Horizon
Continuation	Holds/reclaims $13.20 on a retest	Grinds toward the $14–15 zone, then the upper 52-week band near $16.99	Closes back under $13.20	Days to a few weeks
Failed reclaim	Loses $13.20, drops through $13.00–$12.80	Fade back toward the $12 range and $12.00	A close back above $13.20 flips it positive again	This session onward

Two things keep this honest. First, the move still needs confirmation at the close—an intraday reclaim is not a settlement above the line. Second, the deal is a catalyst for the chart, not a verdict on it: pipeline value does not mechanically push price. The validation improves the odds; the 200-day is the operating instruction.

Verdict

Hold $13.20 and the GSK re-rating stays in play, with the stock aiming up through its 52-week range. Lose $13.20 and the reclaim fails at the first real test, and the sellers get their fade. That is the entire contest, and the next retest decides it.